ES2525007T3 - Nucleósidos ciclopropílicos de uracilo - Google Patents
Nucleósidos ciclopropílicos de uracilo Download PDFInfo
- Publication number
- ES2525007T3 ES2525007T3 ES09764845.5T ES09764845T ES2525007T3 ES 2525007 T3 ES2525007 T3 ES 2525007T3 ES 09764845 T ES09764845 T ES 09764845T ES 2525007 T3 ES2525007 T3 ES 2525007T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- formula
- amino
- hydrogen
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- 229940035893 uracil Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- -1 C1- alkoxy C6 Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000001177 diphosphate Substances 0.000 abstract 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula I:**Fórmula** incluyendo cualesquiera estereoisómeros posibles del mismo, en el que: R1 es hidrógeno o halo; R4 es un éster de monofosfato, difosfato o trifosfato; o R4 es un grupo de fórmula**Fórmula** R7 es fenilo, opcionalmente sustituido con 1, 2 o con 3 sustituyentes, cada uno seleccionado independientemente de halo, alquilo de C1-C6, alquenilo de C3-C6, alcoxi de C1-C6, alcoxicarbonilo de C1-C6, hidroxi y amino; o R7 es naftilo; o R7 es indolilo, o N-alquil C1-C6-oxi-carbonilindolilo; R8 es hidrógeno, alquilo de C1-C6, bencilo; R8' es hidrógeno, alquilo de C1-C6, bencilo; o R8 y R8', junto con el átomo de carbono al que están unidos, forman cicloalquilo de C3-C7; R9 es alquilo de C1-C10, cicloalquilo de C3-C7, alquenilo de bencilo, o fenilo, fenilo el cual puede estar opcionalmente sustituido con 1, 2 ó 3 sustituyentes, cada uno seleccionado independientemente de hidroxi, alcoxi de C1-C6, amino, mono- y di-alquil C1-C6-amino; o su sal farmacéuticamente aceptable o solvato.
Description
E09764845
27-11-2014
- Número de compuesto
- EC50 (M) replicón CC50 (M) (Huh-7) EC50 VIH (M) CC50 (M) (MT-4)
- 4
- 23,9 >98 >98 >98
- 9,2
- >98 >90 >98
- 6
- 16,5 >98 >90 >98
- 7
- 6,1 >90 >90 >64
- 7a
- 10,9 58,4 >60 >50
- 7b
- 3,4 >98 >98 >90
- 8
- 5,9 >98 >98 >98
- 9
- 2,9 >98 >85 >98
- 2,8
- >32 >60 29
- 11
- 2,8 >98 >98 >98
- 12
- 3,1 >98 >98 >98
- 13
- 3,2 >98 >98 >98
- 14
- 3,3 >98 >98 >98
- 3,6
- >98 >60 >60
- 16
- 4,2 >32 >98 >32
- 17
- 4,4 >98 >98 >98
- 18
- 5,1 >98 >98 >64
- 19
- 7,2 >32 >32 >32
- 7,6
- >32 >98 >98
- 21
- 7,8 >98 >98 >80
- 22
- 9,2 >32 1,65 2,1
- 23
- 11,2 >32 >98 >30
- 24
- 12,4 >98 >98 >98
- 23,1
- >32 >98 23
- 26
- 73,7 >98 >98 >98
- 27
- 91,4 >98 >98 >98
- 28
- >98 >98 >98 >98
- 29
- >98 >98 >98 >98
- >98
- >98
- >98
- >98
- 31
- >98 >98 >95 >98
- 32
- >98 >98 >98 >98
- 33
- >98 >98 >98 >98
- 34
- 11,0 >98 - -
- “-” significa que el resultado del ensayo no está disponible
26
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08171006 | 2008-12-08 | ||
| EP08171006 | 2008-12-08 | ||
| PCT/EP2009/066562 WO2010066699A1 (en) | 2008-12-08 | 2009-12-08 | Uracyl cyclopropyl nucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2525007T3 true ES2525007T3 (es) | 2014-12-17 |
Family
ID=40852521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09764845.5T Active ES2525007T3 (es) | 2008-12-08 | 2009-12-08 | Nucleósidos ciclopropílicos de uracilo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8399429B2 (es) |
| EP (1) | EP2373671B1 (es) |
| JP (1) | JP5683480B2 (es) |
| KR (1) | KR20110104000A (es) |
| CN (1) | CN102256991B (es) |
| AP (1) | AP2011005717A0 (es) |
| AR (1) | AR074504A1 (es) |
| AU (1) | AU2009326125B2 (es) |
| BR (1) | BRPI0922681A2 (es) |
| CA (1) | CA2745523C (es) |
| CL (1) | CL2011001364A1 (es) |
| EA (1) | EA020244B1 (es) |
| ES (1) | ES2525007T3 (es) |
| IL (1) | IL212897A (es) |
| MX (1) | MX2011006023A (es) |
| PA (1) | PA8852101A1 (es) |
| SG (1) | SG171973A1 (es) |
| TW (1) | TW201036989A (es) |
| UY (1) | UY32308A (es) |
| WO (1) | WO2010066699A1 (es) |
| ZA (1) | ZA201104231B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3027B1 (ar) * | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
| US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| CN104903339A (zh) * | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
| MX374244B (es) | 2013-03-08 | 2025-03-05 | Nanjing Sanhome Pharmaceutical Co Ltd | Compuesto de fosforamidato de nucleosido novedoso y su uso. |
| CN103848876B (zh) * | 2013-03-25 | 2016-05-11 | 安徽贝克联合制药有限公司 | 一种核苷磷酰胺前药及其制备方法和其应用 |
| CN105705511A (zh) | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
| CN105348342B (zh) * | 2014-09-30 | 2018-09-21 | 南京正大天晴制药有限公司 | 核苷氨基磷酸酯化合物及药物组合物和用途 |
| WO2016073756A1 (en) * | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| CN105801646B (zh) * | 2014-12-31 | 2019-08-16 | 浙江大德药业集团有限公司 | 炔基取代的核苷氨基磷酸酯 |
| WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| MY190867A (en) | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916122A (en) * | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US20010021509A1 (en) * | 1997-10-23 | 2001-09-13 | Sathe Ganesh Madhusudan | cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor |
| TW200500375A (en) * | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| PL219609B1 (pl) * | 2003-02-19 | 2015-06-30 | Masanori Baba | Analogi nukleozydów przeciwwirusowych, zawierająca je kompozycja farmaceutyczna i ich zastosowania |
| AU2004233898B2 (en) * | 2003-04-25 | 2010-12-23 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| AU2006222563A1 (en) * | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| EP2084175B1 (en) | 2006-10-10 | 2010-12-29 | Medivir AB | Hcv nucleoside inhibitor |
-
2009
- 2009-12-03 PA PA20098852101A patent/PA8852101A1/es unknown
- 2009-12-07 TW TW098141651A patent/TW201036989A/zh unknown
- 2009-12-07 AR ARP090104736A patent/AR074504A1/es not_active Application Discontinuation
- 2009-12-08 KR KR1020117015453A patent/KR20110104000A/ko not_active Withdrawn
- 2009-12-08 AP AP2011005717A patent/AP2011005717A0/xx unknown
- 2009-12-08 CN CN200980150162.0A patent/CN102256991B/zh not_active Expired - Fee Related
- 2009-12-08 CA CA2745523A patent/CA2745523C/en not_active Expired - Fee Related
- 2009-12-08 WO PCT/EP2009/066562 patent/WO2010066699A1/en not_active Ceased
- 2009-12-08 ES ES09764845.5T patent/ES2525007T3/es active Active
- 2009-12-08 JP JP2011539051A patent/JP5683480B2/ja not_active Expired - Fee Related
- 2009-12-08 BR BRPI0922681A patent/BRPI0922681A2/pt not_active Application Discontinuation
- 2009-12-08 UY UY0001032308A patent/UY32308A/es unknown
- 2009-12-08 AU AU2009326125A patent/AU2009326125B2/en not_active Ceased
- 2009-12-08 EP EP09764845.5A patent/EP2373671B1/en not_active Not-in-force
- 2009-12-08 EA EA201170780A patent/EA020244B1/ru not_active IP Right Cessation
- 2009-12-08 MX MX2011006023A patent/MX2011006023A/es active IP Right Grant
- 2009-12-08 US US13/130,602 patent/US8399429B2/en not_active Expired - Fee Related
- 2009-12-08 SG SG2011040979A patent/SG171973A1/en unknown
-
2011
- 2011-05-16 IL IL212897A patent/IL212897A/en not_active IP Right Cessation
- 2011-06-07 CL CL2011001364A patent/CL2011001364A1/es unknown
- 2011-06-07 ZA ZA2011/04231A patent/ZA201104231B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2373671B1 (en) | 2014-09-10 |
| SG171973A1 (en) | 2011-07-28 |
| CA2745523C (en) | 2017-07-04 |
| US8399429B2 (en) | 2013-03-19 |
| AU2009326125B2 (en) | 2015-03-12 |
| PA8852101A1 (es) | 2010-07-27 |
| AR074504A1 (es) | 2011-01-19 |
| CN102256991B (zh) | 2015-08-12 |
| CN102256991A (zh) | 2011-11-23 |
| US20110230436A1 (en) | 2011-09-22 |
| EA201170780A1 (ru) | 2011-12-30 |
| IL212897A0 (en) | 2011-07-31 |
| ZA201104231B (en) | 2012-11-28 |
| WO2010066699A1 (en) | 2010-06-17 |
| BRPI0922681A2 (pt) | 2016-01-05 |
| KR20110104000A (ko) | 2011-09-21 |
| AP2011005717A0 (en) | 2011-06-30 |
| JP5683480B2 (ja) | 2015-03-11 |
| JP2012510980A (ja) | 2012-05-17 |
| MX2011006023A (es) | 2011-06-28 |
| TW201036989A (en) | 2010-10-16 |
| IL212897A (en) | 2013-12-31 |
| CL2011001364A1 (es) | 2011-09-23 |
| AU2009326125A1 (en) | 2010-06-17 |
| EA020244B1 (ru) | 2014-09-30 |
| EP2373671A1 (en) | 2011-10-12 |
| UY32308A (es) | 2010-06-30 |
| CA2745523A1 (en) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525007T3 (es) | Nucleósidos ciclopropílicos de uracilo | |
| AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| AR076579A1 (es) | Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc). | |
| PE20160501A1 (es) | Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| CO6180506A2 (es) | Inhibidores de la proteasa ns3 del hcv | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| MX2012008533A (es) | Naftiridinas sustituidas y su uso como inhibidores de syk quinasa. | |
| ECSP14028506A (es) | Nucleósidos de espirooxetano de uracilo | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR081577A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
| AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
| AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
| CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR087017A1 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 | |
| AR068381A1 (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6 |